The relationship between cannabis and women's health occupies a long, uneven historical seam. For millennia this plant moved between sacred, medicinal, and industrial roles, and its treatments for conditions that disproportionately affect women have left traceable footprints in medical manuals, folk knowledge, and legal records. The story is neither a straight march of progress nor simple repression; it is a tangle of cultural values, shifting science, and policy choices that continue to shape what options are visible to patients and clinicians today.
Why this matters Reproductive and hormonal health account for a large portion of medical visits for women across the life course. Painful menstruation, pregnancy-related nausea, menopause symptoms, pelvic pain syndromes, and mood disorders all intersect with quality of life in practical ways. Cannabis, in various forms, has been used historically to address many of these complaints, and understanding that history clarifies why present debates — about safety, access, and research priorities — are so charged.
Cannabis in ancient and traditional systems Cannabis appears in the pharmacopoeias of multiple early civilizations. In China, early agricultural and medicinal texts refer to the plant by the name ma; practitioners used preparations of different plant parts for a variety of ailments. In South Asia cannabis has millennia of ritual and medical use; preparations such as bhang and charas were incorporated into Ayurvedic practice for pain, appetite modulation, and as a soporific. Across Africa and the Middle East, traditional healers also applied cannabis topically or orally to treat pain and inflammation.
These practices were not uniform recipes. Different preparations concentrate different compounds, and methods of extraction — from raw plant material to alcohol-based tinctures and concentrated resins — yield distinct effects. Local customs shaped indications. For example, midwives in certain regions employed cannabis-infused oils to ease labor pains, while in other cultures the plant had more limited, ritualized roles.
19th- and early 20th-century clinical adoption As Western medicine professionalized in the 19th century, botanicals migrated into formal pharmacology. Cannabis extracts entered dispensaries and patent medicines, often marketed for neuralgia, rheumatism, insomnia, and menstrual cramps. British physician Sir John Russell Reynolds is commonly cited for prescribing cannabis tincture to Queen Victoria for menstrual discomfort; the anecdote is recurring in histories because it illustrates how an elite physician framed cannabis as a legitimate remedy for a woman’s gynecological complaint. At roughly the same time, American and European pharmacopoeias began including cannabis preparations. In the United States, cannabis derivatives were listed in sources clinicians consulted well into the early 20th century.
Clinicians of that era worked without isolated compounds like delta-9-tetrahydrocannabinol, THC, or cannabidiol, CBD. They used whole-plant extracts with variable potency. Records show dosing varied widely; physicians relied on titration by effect rather than standardized milligram amounts. That uncertainty is important when evaluating historical reports of efficacy and tolerability.
Industrial hemp and gendered labor Alongside medicinal use, hemp cultivation shaped the economies of many regions. Women participated in processing hemp fiber, a labor-intensive activity requiring retting, beating, and spinning. That economic role meant that communities where hemp was common had notable gendered knowledge about the plant’s properties. Practical familiarity — knowing which parts were fragrant, which leached color, what preparations eased aches from repetitive labor — fed into folk therapeutic practices. When legislation later suppressed hemp cultivation in some places, those knowledge repositories were disrupted.
Criminalization, stigma, and the narrowing of research The 20th century brought dramatic legal and cultural shifts. International agreements and national drug policies increasingly criminalized cannabis, producing a climate where research dried up and clinical practice retracted. For women, the consequences were double-edged. On one side, stigma made it harder for patients to disclose self-medication, leaving clinicians unaware of ministryofcannabis.com potentially important interactions with prescribed drugs such as hormonal contraceptives, antidepressants, or antiepileptics. On the other side, the research freeze meant conditions that primarily affect women received little systematic investigation into cannabis-based options.
The medical literature from midcentury onward reveals a gap rather than clarity. Case reports and observational notes suggested both benefits and adverse effects, but randomized, controlled trials specifically focused on women's health were scarce. The biology of sex differences — hormone cycles, pregnancy physiology, breastfeeding — introduced variables that researchers often excluded to avoid liability or confounding, further entrenching the knowledge gap.
What the modern pharmacology tells us Since the 1990s and accelerating in the 2010s, researchers have isolated cannabinoids and mapped the endocannabinoid system, which plays roles in pain modulation, mood regulation, appetite, and immune response. That biological framework offers plausible mechanisms for why cannabinoids might affect menstrual pain, nausea in pregnancy, mood disorders, and other conditions relevant to women. But mechanistic plausibility is not equivalence to clinical proof.
Contemporary clinical studies provide mixed results. For chronic pain conditions more common in women, some trials show cannabinoids can reduce pain scores modestly, but heterogeneity in formulations, dosages, and patient populations makes synthesis difficult. Data on pelvic pain hemp syndromes like endometriosis are limited; small observational studies and animal models suggest potential analgesic and anti-inflammatory effects, but there is insufficient evidence to recommend cannabis as first-line therapy. In nausea and vomiting, particularly chemotherapy-induced nausea, cannabinoid medications have documented efficacy in certain contexts, but pregnant people are a distinct and understudied population with higher potential for developmental risk, so pregnant patients should approach cannabis use cautiously and under medical guidance.
Safety and trade-offs Evaluating any therapy requires weighing benefits against harms. For cannabis, the most important safety considerations for women include reproductive effects, mental health interactions, and respiratory impacts if smoked.
Reproductive concerns center on pregnancy and breastfeeding. Pregnant people who use cannabis may risk fetal exposure to cannabinoids; some observational studies associate prenatal cannabis exposure with lower birth weight and developmental differences, though confounding factors complicate causal claims. Breast milk can contain cannabinoids, and the pharmacology in infants differs from adults, so many clinicians advise against use during pregnancy and breastfeeding when possible.
Mental health interactions are another key area. For individuals predisposed to anxiety, psychosis, or mood instability, high-THC products can exacerbate symptoms. Women have different epidemiologic patterns of certain psychiatric conditions, and hormonal cycles can influence both mood and drug metabolism, so personalized assessment is essential.
Respiratory harms stem from inhalation methods. Smoking plant material introduces combustion products, which carry risks independent of cannabinoids. Vaporization or oral ingestion reduces those particular risks but introduces variability in absorption and onset, which matters for dosing and safety.
Clinical judgment therefore becomes an exercise in trade-offs and context. For a midlife patient with refractory neuropathic pain who has tried multiple medications without relief, an oral CBD-dominant product might present an acceptable risk profile in shared decision making. For a young person planning pregnancy, the calculus shifts toward minimizing exposure.
Gendered medicine and research gaps Historically, clinical research underrepresented women, and until more recently sex-disaggregated analyses were rare. Those gaps persist in cannabis research. Key questions remain: how do cyclical hormone changes affect cannabinoid pharmacokinetics? Does menopause alter response to cannabinoids or the endocannabinoid tone? How do commonly used hormonal treatments, including oral contraceptives and hormone replacement therapy, interact with cannabinoids metabolized by the liver’s cytochrome systems?
Filling these gaps requires trials that deliberately include women across reproductive stages, capture contraceptive and pregnancy intentions, and stratify results by hormonal status. Observational cohorts can help identify real-world patterns, but randomized designs are necessary to move from hypothesis to practice.
Practical considerations for clinicians and patients Clinicians who encounter patients using or considering cannabis must navigate a complex mix of evidence, law, and patient goals. Harm reduction is a viable, ethically defensible approach when abstinence is unrealistic or when legal and medical contexts make prohibition counterproductive.
A short checklist to guide clinical conversations
- Describe current symptoms and previous treatments tried, including doses and durations. Ask explicitly about cannabis use, preparation (smoked, vaped, edible, topical, tincture), frequency, and source. Discuss reproductive plans, pregnancy status, and breastfeeding intentions, and explain known risks and uncertainties. Consider potential drug interactions, especially with hormonal agents, anticoagulants, and psychotropics, and consult pharmacology references if needed. Agree on realistic goals, monitoring strategies, and follow-up, including objective measures when possible.
Those questions help shift conversations from moralizing to practical problem-solving. When patients are using cannabis, clinicians should document products and quantities, counsel about safer routes (for example, avoiding smoking), and set clear parameters for reassessment.
Regulatory and social dimensions Legal status varies widely between jurisdictions and even within countries. Criminalization historically affected women differently than men; for example, prosecutions related to parental cannabis use sometimes led to child custody interventions rather than therapeutic referrals. In recent decades, legalization and medical cannabis programs have expanded access for some, but regulatory frameworks often prioritize adult recreational use over structured medical research, creating mismatches between policy and clinical evidence needs.
Social determinants also matter. Access to reputable products, reliable dosing information, and nonjudgmental medical advice depends on socioeconomic status, legal exposure, and cultural context. Communities with historical distrust of medical institutions may be less likely to seek clinician guidance, even when legal access exists. Addressing those disparities requires both policy changes and local outreach.
Anecdotes that illustrate complexity A reproductive endocrinologist I spoke with recounted a patient who used a THC-CBD balanced oral preparation to manage severe dysmenorrhea when NSAIDs and hormonal therapies failed. The patient reported dramatic pain relief and regained function at work. She stopped the product after becoming pregnant, and the clinician supported cessation while monitoring symptoms and discussing alternative pain strategies. This case highlights pragmatic decision making: treat what is a disabling symptom, but reassess when the reproductive context changes.
Another example comes from rural midwifery traditions where topical cannabis salves were used for perineal soreness and to ease joint pain from repetitive childcare tasks. Those remedies were low-dose, topically applied, and rarely associated with systemic effects. When legal restrictions disrupted local hemp economies, these pragmatic, community-based solutions disappeared, and replacements were not straightforward.
Where research should go next Priority areas include randomized controlled trials for pelvic pain conditions, head-to-head studies comparing cannabinoid formulations in specific gynecologic indications, and pharmacokinetic research across hormonal states. Safety-focused work on pregnancy and lactation needs ethically designed observational studies with careful confounder control to provide clearer risk estimates. Finally, qualitative research that captures patient experiences, preferences, and barriers to care will inform patient-centered policies and clinical guidelines.
Practical recommendations for patients seeking information Patients asking about cannabis should expect balanced counsel. Clinicians should acknowledge the limited but evolving evidence base, avoid categorical endorsements, and emphasize concrete risk-reduction steps: prefer noncombustible routes, choose lower THC and documented CBD products when anxiety or psychosis risk exists, and stop use during pregnancy and breastfeeding unless a clinician advises otherwise in a situation where benefits outweigh risks. Keep lines of communication open; clinicians perform better care when they know what patients are using.
Final perspective The history of cannabis in women's health is a layered narrative of utility, prohibition, resilience, and knowledge gaps. Traditional uses provided practical remedies for menstrual pain, childbirth-related discomfort, and laborious work injuries. Medical adoption in the 19th century showed clinical interest, while 20th-century criminalization narrowed both access and research. Today, growing biomedical understanding and changing laws open opportunities to reexamine cannabis with better science and patient-centered frameworks. The work ahead is to convert plausible mechanisms and historical signals into rigorous evidence, while keeping human contexts — reproductive plans, psychological health, social risk — at the center of clinical judgment.